

No Plan or PBM Rebates in Part B, Yet Substantial Price Increases

Selected Part B Drugs with Price Increases from 2017 to 2018

Brand Name	2012 Price per Part B prescription	Estimated 2017 Price per Part B prescription*	% Price Increase 2012-17	Estimated 2018 Price per Part B prescription*	% Price Increase 2017-18
Miacalcin	\$461	\$16,375	3,449%	\$19,266	18%
Krystexxa	\$2,717	\$19,163	605%	\$21,127	10%
Teflaro	\$110	\$399	263%	\$439	10%
Bicillin	\$41	\$106	159%	\$120	13%
Rituxan	\$5,125	\$6,890	34%	\$7,416	8%
Orencia	\$1,636	\$2,849	74%	\$3,020	6%

*Estimated inflation adjusted price = 2012 price * weighted average manufacturer increase in list price per unit. Not affected by changes in numbers of units per claim, or mix of doses/dosage forms. Estimated 2018 price through Q3 2018.

During study years PBMs were not involved in Medicare Part B program, so no PBM rebates were involved. Analysis included drugs with Part B spending data for full period 2012-16.

Source: Visante and PCMA analysis of data from CMS and SSR Health, 2019.